NCT03702738View on ClinicalTrials.gov

Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Tuberculosis, Pulmonary

Interventions

DRUG

N-acetyl cysteine

NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.

Trial Locations (1)

Unknown

NIMR-Mbeya Medical Research Centre, Mbeya

All Listed Sponsors

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

lead

The Aurum Institute NPC

OTHER

NCT03702738 - Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter